37 results about "Hepatitis B virus surface" patented technology

The invention relates to application of B-ring ethyoxyl flavanonol in preparing medicaments for treating hepatitis B viruses, in particular to application of a compound as shown in a formula (1) or a medicinal salt thereof in preparing medicaments for clearing away hepatitis B virus surface antigens (HBsAg) and hepatitis B e-antigen (HBeAg) and medicaments for inhibiting the duplication of hepatitis B virus desoxyribonucleic acid (HBV DNA). The compound or the medicinal salt thereof has extremely obvious activity on inhibiting the HBsAg and the HBeAg, and in the presence of a concentration of 20 microgram / milliliter, the intensities for clearing away the HBsAg and the HBeAg of the compound or the medicinal salt thereof are respectively 99.8 percent and 48.5 percent and are 6.2 times and 2.7 times of that of alpha-interferon which is a positive control medicament. More importantly, in the presence of the concentration, the inhibition ratio of the compound or the medicinal salt thereof to the HBV DNA is 64.7 percent, and the activity is 1.7 times of that of the alpha-interferon. Accordingly, the flavone lignan or the medicinal salt thereof can be expected to be used for preparing non-nucleoside medicaments for treating infectious diseases of the hepatitis B viruses.

The invention relates to application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B, in particular to application of silybin ester flavonolignan substituted by ethoxycarbonyl methyl on the ring A or a pharmaceutically acceptable salt thereof for preparing medicaments for reducing the hepatitis B virus surface antigen (HBsAg), suppressing the HBV (Hepatitis B Virus) DNA replication and treating HBV infection diseases. The flavonolignan has quite obvious activity on suppressing the HBsAg, and in the presence of a concentration of 100 micrograms / milliliter, the intensity of the flavonolignan for clearing away the HBsAG exceeds that of alpha-interferon which is a positive control medicament by 3.3 times. Meanwhile, in the presence of a concentration of 20 micrograms / milliliter, suppression ratio of the compound to the HBV DNA is close to 60 percent. The pharmacodynamical results indicate that the flavonolignan or the pharmaceutically acceptable salt thereof can be expected to be used for preparing the medicaments for treating the HBV infection diseases.

The invention relates to peptides derived from HBV L protein for the prevention and treatment of Hepatitis B virus (HBV) infection, screening method for removing antigenicity of these peptides and the deantigenic derivative peptide screened through the method, wherein the HBV surface L protein pre-S1 region contains key amino acid sequence of the virus adhesion cell surface acceptor and antigenic amino acid sequence bonding with the anti-L protein antibody. The polypeptides at the HBV surface L protein pre-S1 region can suppress HBV infection to cells. The invention also provides the screening method for removing the antigenicity of these polypeptides.

The invention relates to a nanometer magnetic particle chemiluminiscence kit, a preparation method and a detection method of a hepatitis B virus surface-antibody. The kit comprises a solution containing hepatitis B virus surface-antibody marked by fluorescein, a suspension liquid of the magnetic particle coated with a fluorescein antibody and a solution containing the hepatitis B virus surface-antibody marked by alkaline phosphatase. According to the invention, quantitative detection of the hepatitis B virus surface-antibody can carried out at lower cost, higher accuracy and higher precision.

The invention discloses a kit and a method for detecting hepatitis B virus surface antigen (HBsAg). The detection kit is used for marking hepatitis B virus surface antibody (HBsAb) by using metalloporphyrin obtained by using water-soluble A3B type metalloporphyrin to mark the HBsAb. The detection kit and the detection method have the advantages that: (1) free metalloporphyrin molecules are separated from a coupled substance easily after an A3B type metalloporphyrin complex is coupled with the HBsAb to obtain a high-purity labelled antibody, so that non-specific adsorption background signals are reduced when the HBsAg is detected by chemical luminescence immunodetection, and detection sensitivity is greatly improved; (2) the method is simple, convenient and quick; automation is realized easily; and specificity of immunoreaction, high sensitivity of chemical luminescence reaction and stability of a chemical marker are achieved; and (3) a new method is provided for detecting the HBsAg quickly and accurately, and preventing and treating the hepatitis B virus.

The subject invention is hollow nanoparticles that comprise particle-forming first proteins (e.g. hepatitis B virus surface-antigen protein), containing a bio-recognizing molecule for recognizing a specific cell, wherein at least one of the first proteins interacts with a second protein (e.g. hepatitis B virus core-antigen protein) forming a capsid structure. With this structure, the present invention provides hollow nanoparticles, that allow transfer of a substance to a specific cell or tissue, and can be manufactured with stable productivity. The present invention further provides a drug made of the hollow nanoparticles.

The invention relates to a suspension chip detection method for simultaneously detecting hepatitis B virus, hepatitis C virus, treponema pallidum and human immunodeficiency virus pathogens. Plastic color coded microspheres with diameter of between 5.5 and 6.5 mu m are taken as vectors for a suspension chip; and the carriers are coated with monoclonal hepatitis B virus surface antibodies, HIV1, gP41 antigens, HCV NS3 antigens or treponema pallidum TP15 antigens. Through the suspension chip, the hepatitis B virus, hepatitis C virus, treponema pallidum and human immunodeficiency virus pathogens in a sample to be detected can be very conveniently and quickly detected at the same time; and the method has the advantages of accurate and reliable detection result, high specificity, small using amount of samples and high-throughput detection.

The present invention is a composition that comprises at least two hepatitis B virus surface antigens (HBsAgs), fragments thereof and / or nucleic acids encoding them, the HBsAgs differing in HBV genotype in the S region and / or pre-S1 region and the composition containing no HBV core antigen (HBcAg) or nucleic acid encoding that antigen. The present invention also includes pharmaceutical compositions, especially vaccines, comprising these compositions for the prevention and / or treatment of an HBV infection or an HBV-mediated disease. The present invention further includes a method of preparing a patient-specific medicament for the therapeutic treatment of hepatitis B.

An application of staphylococcal enterotoxin A gene and its coding protein in obviously improving the responsiveness of animal to DNA vaccine and intensifying the immunogenicity of various DNA vaccines for hepatitis B virus, malaria, etc is disclosed.

The invention discloses a preparation method of a hepatitis B virus surface protein adsorbent. The method uses amino acid treatment to connect adsorption microspheres of a ligand to make the ligand firmly combined, so the shedding probability of the hepatitis B virus surface protein adsorbent is reduced, and the application safety of the hepatitis B virus surface protein adsorbent is improved.

The present invention relates to diagnostic reagents for antibody against hepatitis B surface antigen and for antibody against hepatitis B virus using a sandwich immunoassay as a quantitative or qualitative analysis method for antibody against hepatitis B surface antigen and for antibody against hepatitis B virus, characterized in that each diagnostic reagent comprises a pair of hepatitis B surface antigens which are different each other and composed of primary antigen immobilized on a solid support and secondary antigen conjugated to a marker. Also, the present invention relates to preparation methods thereof. Further, the present invention relates to diagnostic methods for antibody against hepatitis B surface antigen and for antibody against hepatitis B virus. In accordance with the present invention, there are provided diagnostic reagents and methods with markedly enhanced sensitivity and specificity in comparison to diagnostic reagents and methods in which single kind of hepatitis B virus surface antigens are used.

The invention discloses an extrasin alpha original gene new usage, which is characterized by the following: the ProT alpha improves the reactivity of animal reacting to DNA vaccin observably, which can use as immune original-nature reinforcing adjuvant of DNA vaccin; the extrasin alpha original gene strengthens immune original-nature of hepatitis B virus surface antigen DNA vaccin, malarial disease multiple-epitope antigen DNA vaccin and kinds of DNA vaccines, which possesses broad-spectrum nature.

The invention relates to a hepatitis B virus surface protein mutant, in particular, relates to an S protein mutant which can inhibit hepatitis B virus (HBV) replication and / or inhibit surface antigen (HBsAg) expression and secretion, and further relates to a biological material related to the S protein mutant and an application of the S protein mutant in HBV resistance. In-vitro tests show that an S-L13R / E / D / K mutant can be used for inhibiting the replication of HBV in Huh7 cells and inhibiting the expression and secretion of HBsAg; in an Adv / prcccDNA hepatitis B chronic mouse model, blood HBsAg is converted into negative, surface antibody HBsAb can appear in blood, HBeAg level and HBV DNA level in serum are also converted into negative, and no obvious ALT rise is caused in the negative conversion process, so that the safety of the antibody is proved, the S protein mutant has obvious influence on the secretion of HBsAg of different genotypes of HBV, and the S protein mutant of different genotypes has obvious influence on the secretion of HBsAg of the same genotype of HBV, so that a new method is provided for clinically treating chronic hepatitis B.

The invention relates to application of substituted silybin ester in preparing a medicament for treating virus hepatitis B, in particular to application of 23-position ethyl-malonyl substituted silybin ester or medicinal salt thereof in preparing a medicament for reducing hepatitis B virus surface antigen HBsAg, inhibiting HBV DNA replication and treating hepatitis B virus infected diseases. The flavonolignan has remarkable effect of inhibiting HBsAg activity, and the strength of the flavonolignan at the concentration of 100 micrograms per milliliter for clearing the HBsAg is two times and half that of a positive control medicament alpha-interferon; and meanwhile, the compound has strong inhibiting activity on the HBV DNA. Pharmacodynamical results show that the flavonolignan or the medicinal salt thereof can be expected to be used for preparing the medicament for reducing hepatitis B virus surface antigen, inhibiting HBV DNA replication and treating the hepatitis B virus infected diseases.

The invention discloses a new use of staphylococcal enterotoxin gene A. An experiment carried out by the author of the invention shows that the staphylococcal enterotoxin gene A can obviously improve the reactivity of animals to DNA vaccines and can be used as an adjuvant for improving the immunogenicity of the DNA vaccines or recombinant subunit vaccines. The staphylococcal enterotoxin gene A can improve the immunogenicity of various DNA vaccines, such as HBV surface antigen DNA vaccine and malaria multi-epitope antigen DNA vaccine, etc., has broad spectrum, and is a rare adjuvant for improving the immunogenicity of the DNA vaccines. Therefore, the staphylococcal enterotoxin gene A has great significance in the production and the application of the DAN vaccines and the recombinant subunit vaccines.

Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.

The invention discloses a humanized single chain antibody of anti-hepatitis B virus surface antigen a determinant, the amino acid sequence thereof is SEQ ID NO: 1. The VH amino acid sequence of the antibody is SEQ ID NO: 2, and the VL amino acid sequence of the antibody is SEQ ID NO: 3. The humanized single chain antibody of the anti-hepatitis B virus surface antigen a determinant is used for preparing preventive passive immunity drug or preparing medicines for treating chronic viral hepatitis B.

The invention provides a fusion gene encoding a new-type Hepatitis B virus surface antigen and the protein thereof. The nucleotide sequence, encoding Hepatitis B virus preS2 antigen (Met1-Gly26) containing B-cell and T-cell epitopes and polymerized albumin binding site, is fused to 3' terminal of Hepatitis B virus surface antigenic main protein S gene, then the expression is carried out in yeast expression system. The expressed products, possessing simultaneously antigenicity of S and preS2, are assembled into virus-like particles with diameter of about 20-35nm and are potential for developing novel Hepatitis B vaccines.

The invention relates to application of B-ring ethyoxyl flavanonol in preparing medicaments for treating hepatitis B viruses, in particular to application of a compound as shown in a formula (1) or a medicinal salt thereof in preparing medicaments for clearing away hepatitis B virus surface antigens (HBsAg) and hepatitis B e-antigen (HBeAg) and medicaments for inhibiting the duplication of hepatitis B virus desoxyribonucleic acid (HBV DNA). The compound or the medicinal salt thereof has extremely obvious activity on inhibiting the HBsAg and the HBeAg, and in the presence of a concentration of20 microgram / milliliter, the intensities for clearing away the HBsAg and the HBeAg of the compound or the medicinal salt thereof are respectively 99.8 percent and 48.5 percent and are 6.2 times and 2.7 times of that of alpha-interferon which is a positive control medicament. More importantly, in the presence of the concentration, the inhibition ratio of the compound or the medicinal salt thereof to the HBV DNA is 64.7 percent, and the activity is 1.7 times of that of the alpha-interferon. Accordingly, the flavone lignan or the medicinal salt thereof can be expected to be used for preparing non-nucleoside medicaments for treating infectious diseases of the hepatitis B viruses.

The invention relates to application of a B / E ring substituted silybin for preparing a medicament for treating virus hepatitis B, in particular to the application of a B ring ethoxy and E ring methoxy substituted silybin ester or medicinal salts thereof for preparing the medicament for eliminating hepatitis B virus surface antigens and hepatitis B e antigen and inhibiting HBV and DNA replication. The medicament has accurate activity of inhibiting HBsAg and HbeAg, and respective intensity of 18.5% and 23.0% in eliminating HBsAg and HbeAg at the concentration of 100 microgram / ml, which exceeds the positive control medicament of an alpha-interferon; and meanwhile, 23.3% inhibition ratio on HBV and DNA is displayed at the concentration of 100 microgram / ml; and therefore, flavonoid lignans or a medicinal salt thereof are proved to have the efficacy of inhibiting HbsAg, HbeAg, HBV and DNA. The application is predictably used for preparing the non-nucleoside medicament for eliminating HBsAg and HbeAg, inhibiting HBV and DNA replication and treating hepatitis B virus infectious diseases.

The invention discloses a special-effect oral liquid for treating hepatitis B; the special-effect oral liquid is prepared by decoction and concentration of capillary artemisia, fructus gardeniae, rheum officinale, cortex phellodendri, rhizoma coptidis, dandelion, radix scrophulariae, fructus forsythiae, radix rehmanniae recen, toad venom, brucea javanica, herba lysimachiae, sowthistle tasselflower herb, cortex cinnamomi, rhizoma acori graminei, rhizoma chuanxiong, radix salviae miltiorrhizae, radix curcumae, caulis spatholobi, hawthorn, Chinese yam, radix astragali, jujube, radix morindae officinalis, rhizoma curculiginis, fructus psoraleae, kernels, rhizoma cibotii, radix polygoni multiflori, longan aril, Chinese wolfberry, fructus ligustri lucidi, radix ophiopogonis, bitter apricot kernel, lotus seed, ganoderma lucidum, radix saposhnikoviae, radix angelicae tuhuo, radix puerariae, radix bupleuri, rhizoma cimicifugae, mung beans, pericarpium citri reticulatae, and endothelium corneum gigeriae galli. The pure traditional Chinese medicine preparation has stronger functions of cleaning hepatitis B viruses, regulating immunity, repairing damaged liver cells, improving hepatic microcirculation, and promoting hepatitis B virus surface antibodies to be turned into positive and hepatitis B surface antigens, hepatitis B e antigens, hepatitis B e antibodies and hepatitis B core antibodies to be turned into negative, has the advantages of exact curative effect, short treatment course and quick acting, and allows the disease not to relapse after the disease is cured.

The invention relates to hepatitis B virus (HBV) surface L protein derived peptide which is used for preventing and curing HBV infection, a screening method which is used for removing polypeptide antigenicity and antigenicity-removing derived peptide which is screened and obtained through the screening method. An HBV surface L protein pre-S1 area has a key amino acid sequence of virus adherent cell surface receptors and an antigenicity amino acid sequence which is combined with antibody against L protein. Polypeptide in the HBV surface L protein pre-S1 area can inhibit the infection of the HBV on cells. The invention also provides the screening method which is used for removing polypeptide antigenicity. The antigenicity-removing derived peptide is screened, can inhibit HBV infection and does not combine with the antibody.; Therefore, the mutual interference between natural L protein derived peptide and the antibody against the L protein during HBV infection inhibition is avoided, and both the antigenicity-removing derived peptide and the antibody against the HBV surface L protein can inhibit the HBV infection.

The invention relates to a culture medium supplement, a cell culture medium containing the supplement and applications thereof, the culture medium supplement comprising proline, asparagine and histidine, and / or, transferrin and insulin . The above-mentioned medium supplements can be used for culturing CHO cells specifically expressing hepatitis B virus surface antigen by adding 20-30 mL / L newborn bovine serum to glutamine-free DMEM. The concentration of newborn calf serum used in the cell culture medium provided by the invention is as low as 2%, and it can be directly used for culturing CHO cells by adding specific components, without domesticating the CHO cells, and at the same time, the HBV surface antigen can be expressed in the CHO cells Levels rose, rising 16% to 40% in 13 days.

When preparing HBsAg for use in a combination vaccine, it us known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.

The invention relates to application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B, in particular to application of silybin ester flavonolignan substituted by ethoxycarbonyl methyl on the ring A or a pharmaceutically acceptable salt thereof for preparing medicaments for reducing the hepatitis B virus surface antigen (HBsAg), suppressing the HBV (Hepatitis B Virus) DNA replication and treating HBV infection diseases. The flavonolignan has quite obvious activity on suppressing the HBsAg, and in the presence of a concentration of 100 micrograms / milliliter, the intensity of the flavonolignan for clearing away the HBsAG exceeds that of alpha-interferon which is a positive control medicament by 3.3 times. Meanwhile, in the presence of a concentration of 20 micrograms / milliliter, suppression ratio of the compound to the HBV DNA is close to 60 percent. The pharmacodynamical results indicate that the flavonolignan or the pharmaceutically acceptable salt thereof can be expected to be used for preparing the medicaments for treating the HBV infection diseases.

The invention relates to hepatitis B virus (HBV) surface L protein derived peptide which is used for preventing and curing HBV infection, a screening method which is used for removing polypeptide antigenicity and antigenicity-removing derived peptide which is screened and obtained through the screening method. An HBV surface L protein pre-S1 area has a key amino acid sequence of virus adherent cell surface receptors and an antigenicity amino acid sequence which is combined with antibody against L protein. Polypeptide in the HBV surface L protein pre-S1 area can inhibit the infection of the HBV on cells. The invention also provides the screening method which is used for removing polypeptide antigenicity. The antigenicity-removing derived peptide is screened, can inhibit HBV infection and does not combine with the antibody. Therefore, the mutual interference between natural L protein derived peptide and the antibody against the L protein during HBV infection inhibition is avoided, and both the antigenicity-removing derived peptide and the antibody against the HBV surface L protein can inhibit the HBV infection.

The present invention provides a method for detecting hepatitis B surface antigen (HBsAg) by inductively coupled plasma mass spectrometry (ICP-MS), which involves covalently linking hepatitis B virus surface antibody (HBsAb) to metal colloid particles with activated carboxyl groups , the HBsAg in the serum and the colloidal particle-labeled HBsAb combine to form an immune complex through a specific reaction; the colloidal particles are dissociated from the immune complex under acidic conditions, and then the metal ion signal is detected by ICP-MS, thereby indirectly detecting HBsAg . Since each colloidal particle can be connected with one or more antibody molecules, the sensitivity of the detection is greatly improved; this method overcomes the disadvantages of low accuracy of the traditional colloidal gold immunochromatography and enzyme-linked immunoassay. It has excellent accuracy and high sensitivity, and the immunoassay detection is convenient and rapid, which broadens the application of ICP-MS in immunoassay.

The invention discloses a new use of staphylococcal enterotoxin gene A. An experiment carried out by the author of the invention shows that the staphylococcal enterotoxin gene A can obviously improve the reactivity of animals to DNA vaccines and can be used as an adjuvant for improving the immunogenicity of the DNA vaccines or recombinant subunit vaccines. The staphylococcal enterotoxin gene A can improve the immunogenicity of various DNA vaccines, such as HBV surface antigen DNA vaccine and malaria multi-epitope antigen DNA vaccine, etc., has broad spectrum, and is a rare adjuvant for improving the immunogenicity of the DNA vaccines. Therefore, the staphylococcal enterotoxin gene A has great significance in the production and the application of the DAN vaccines and the recombinant subunit vaccines.